Alessia Moioli

机构：University of Verona · ORCID：0000-0002-8650-4941

发表论文 19 篇 · 总被引 71 次 · h-index 5

代表论文

• Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study (2024 · Cancer · 被引 14)
• High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma (2022 · Hematological Oncology · 被引 14)
• Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study (2025 · Leukemia Research · 被引 8)
• Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey (2024 · Annals of Hematology · 被引 7)
• Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study (2025 · The Lancet Haematology · 被引 6)
• TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer (2025 · Journal of Clinical Medicine · 被引 3)